Top

19-09-2017 | Gastrointestinal cancers | Article

Individualized Treatment Sequencing Selection Contributes to Optimized Survival in Patients with Rectal Cancer and Synchronous Liver Metastases

Journal: Annals of Surgical Oncology

Authors: Claudius Conrad, MD, PhD, Jean-Nicolas Vauthey, MD, Okuno Masayuki, MD, PhD, Rahul A. Sheth, MD, Suguru Yamashita, MD, PhD, Guillaume Passot, MD, Christina E. Bailey, MD, MSCI, Daria Zorzi, MD, Scott Kopetz, MD, PhD, Thomas A. Aloia, MD, Y. Nancy You, MD, MHSc

Publisher: Springer International Publishing

Abstract

Background

The optimal treatment sequence for patients with advanced rectal cancer and synchronous resectable liver metastases is controversial. We examined the outcomes associated with an individualized selection of classic, reversed, or combined approaches.

Methods

Between 1999 and 2014, 268 patients with rectal cancer and synchronous liver-only metastases underwent curative-intent multimodality therapy. Demographics and tumor and treatment details were reviewed. Survival outcomes were examined across treatment sequences and time periods (1999–2003, 2004–2008, and 2009–2014).

Results

Overall, 150 (56.0%) patients underwent primary tumor resection first (‘classic’ approach), 44 (16.4%) patients underwent simultaneous resection of the primary and liver metastases (‘combined’ approach), and 74 (27.6%) patients underwent liver resection first (‘reversed’ approach). Patients who underwent the reversed approach had more liver metastases (3 [2–5]) at presentation (vs. 1 [1–2.5] in the combined approach or 1 [1–3] in the classic approach; p < 0.001). Over time (from 1999 to 2003, to 2009 to 2014), both patients undergoing curative-intent treatment (62–122 patients) and the relative proportion of patients undergoing the reversed approach (6.4–37.7%) significantly increased. Despite higher disease burden, the 5-year overall survival (OS) was higher for patients treated in 2009–2014 versus those treated in 1999–2003 (76% vs. 45%; p < 0.002). Two hundred and ten patients (78%) were rendered free of disease; however, 58 were not due to disease progression or treatment complications, and their 5-year OS was poor at 6%.

Conclusions

Individualized selection of treatment sequence based on the liver metastases and primary tumor disease burden allowed most patients to complete resection of all gross disease, and is associated with a 5-year OS rate approaching that for stage III rectal cancer in the most recent era.

Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg. 2006;244(2):254–259.CrossRefPubMedPubMedCentral

Conrad C, You N, Vauthey JN. In patients with colorectal liver metastases, can we still rely on number to define treatment and outcome? Oncology (Williston Park). 2013;27(11):1078, 1083–1074, 1086.

Butte JM, Gonen M, Ding P, et al. Patterns of failure in patients with early onset (synchronous) resectable liver metastases from rectal cancer. Cancer. 2012;118(21):5414–5423.CrossRefPubMed

Merkow RP, Bentrem DJ, Cohen ME, et al. Effect of cancer surgery complexity on short-term outcomes, risk predictions, and hospital comparisons. J Am Coll Surg. 2013;217(4):685–693.CrossRefPubMed

Farid SG, Aldouri A, Morris-Stiff G, et al. Correlation between postoperative infective complications and long-term outcomes after hepatic resection for colorectal liver metastasis. Ann Surg. 2010;251(1):91–100.CrossRefPubMed

Adam R, de Gramont A, Figueras J, et al. Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus. Cancer Treat Rev. 2015;41(9):729–741.CrossRefPubMed

Mentha G, Majno PE, Andres A, Rubbia-Brandt L, Morel P, Roth AD. Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary. Br J Surg. 2006;93(7):872–878.CrossRefPubMed

Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386–422. doi:10.1093/annonc/mdw235.CrossRefPubMed

Mentha G, Majno P, Terraz S, et al. Treatment strategies for the management of advanced colorectal liver metastases detected synchronously with the primary tumour. Eur J Surg Oncol. 2007;33(Suppl 2):S76–83.CrossRefPubMed

10.

You YN, Eng C, Aloia T. Multidisciplinary management of stage IV colon cancer. Semin Colon Rectal Surg. 2016;27(4):213–218.CrossRef

11.

Rodel C, Graeven U, Fietkau R, et al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2015;16(8):979–989.CrossRefPubMed

12.

Gall TM, Basyouny M, Frampton AE, et al. Neoadjuvant chemotherapy and primary-first approach for rectal cancer with synchronous liver metastases. Colorectal Dis. 2014;16(6):O197–205.CrossRefPubMed

13.

Boostrom SY, Vassiliki LT, Nagorney DM, et al. Synchronous rectal and hepatic resection of rectal metastatic disease. J Gastrointest Surg. 2011;15(9):1583–1588.CrossRefPubMed

14.

Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371(9617):1007–1016.CrossRefPubMedPubMedCentral

15.

Chun YS, Vauthey JN, Boonsirikamchai P, et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA. 2009;302(21):2338–2344.CrossRefPubMedPubMedCentral

16.

Shindoh J, Chun YS, Loyer EM, Vauthey JN. Non-size-based response criteria to preoperative chemotherapy in patients with colorectal liver metastases: the morphologic response criteria. Curr Colorectal Cancer Rep. 2013;9(2):198–202.CrossRefPubMedPubMedCentral

17.

Shindoh J, Loyer EM, Kopetz S, et al. Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases. J Clin Oncol. 2012;30(36):4566–4572.CrossRefPubMedPubMedCentral

18.

Ayez N, Burger JW, van der Pool AE, et al. Long-term results of the “liver first” approach in patients with locally advanced rectal cancer and synchronous liver metastases. Dis Colon Rectum. 2013;56(3):281–287.CrossRefPubMed

19.

Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731–1740.CrossRefPubMed

20.

Tzeng CW, Aloia TA, Vauthey JN, et al. Morbidity of staged proctectomy after hepatectomy for colorectal cancer: a matched case-control analysis. Ann Surg Oncol. 2013;20(2):482–490.CrossRefPubMed

21.

Smith JD, Butte JM, Weiser MR, et al. Anastomotic leak following low anterior resection in stage IV rectal cancer is associated with poor survival. Ann Surg Oncol. 2013;20(8):2641–2646.CrossRefPubMed

22.

Yamashita S, Sheth RA, Niekamp AS, et al. Comprehensive Complication Index predicts cancer-specific survival after resection of colorectal metastases independent of RAS mutational status. Ann Surg. 2016;24: 2595.

23.

Silberhumer GR, Paty PB, Temple LK, et al. Simultaneous resection for rectal cancer with synchronous liver metastasis is a safe procedure. Am J Surg. 2015;209(6):935–942.CrossRefPubMed

24.

Abbott DE, Cantor SB, Hu CY, et al. Optimizing clinical and economic outcomes of surgical therapy for patients with colorectal cancer and synchronous liver metastases. J Am Coll Surg. 2012;215(2):262–270.CrossRefPubMedPubMedCentral